Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ninh M La-Beck

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Asia-Pacific Journal of Oncology Nursing|September 5, 2024
Updates and emerging trends in the management of immune-related adverse events associated with immune checkpoint inhibitor therapyNinh M La-Beck, Jesuwapelumi Owoso
Frontiers in Immunology|April 22, 2017
Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer ChemotherapyNinh M La-Beck, Alberto A Gabizon
Frontiers in Pharmacology|March 28, 2019
Harnessing Liposome Interactions With the Immune System for the Next Breakthrough in Cancer Drug DeliveryNinh M La-Beck, Xinli Liu, Laurence M Wood
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|December 4, 2016
New insights and evolving role of pegylated liposomal doxorubicin in cancer therapyAlberto A Gabizon, Yogita Patil, Ninh M La-Beck
Frontiers in Immunology|January 25, 2021
Nanoparticle-Induced Complement Activation: Implications for Cancer NanomedicineNinh M La-Beck, Md Rakibul Islam, Maciej M Markiewski
Asia-Pacific Journal of Oncology Nursing|April 2, 2019
Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical GuidelinesSaralinh Trinh, Alex Le, Sajida Gowani, et al.
BMJ Oncology|January 31, 2025
Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspectiveAlberto A Gabizon, Shira Gabizon-Peretz, Shadan Modaresahmadi, et al.
Advanced Drug Delivery Reviews|June 12, 2020
Translational considerations in nanomedicine: The oncology perspectiveAlberto A Gabizon, Rafael T M de Rosales, Ninh M La-Beck
Therapeutics and Clinical Risk Management|March 7, 2017
Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in contextAlexander D Le, Saeed K Alzghari, Gary W Jean, et al.
Seminars in Cancer Biology|December 25, 2019
Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatmentNinh M La-Beck, Xinli Liu, Hilary Shmeeda, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Asia-Pacific Journal of Oncology Nursing|September 5, 2024
Updates and emerging trends in the management of immune-related adverse events associated with immune checkpoint inhibitor therapyNinh M La-Beck, Jesuwapelumi Owoso
Frontiers in Immunology|April 22, 2017
Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer ChemotherapyNinh M La-Beck, Alberto A Gabizon
Frontiers in Pharmacology|March 28, 2019
Harnessing Liposome Interactions With the Immune System for the Next Breakthrough in Cancer Drug DeliveryNinh M La-Beck, Xinli Liu, Laurence M Wood
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|December 4, 2016
New insights and evolving role of pegylated liposomal doxorubicin in cancer therapyAlberto A Gabizon, Yogita Patil, Ninh M La-Beck
Frontiers in Immunology|January 25, 2021
Nanoparticle-Induced Complement Activation: Implications for Cancer NanomedicineNinh M La-Beck, Md Rakibul Islam, Maciej M Markiewski
Asia-Pacific Journal of Oncology Nursing|April 2, 2019
Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical GuidelinesSaralinh Trinh, Alex Le, Sajida Gowani, et al.
BMJ Oncology|January 31, 2025
Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspectiveAlberto A Gabizon, Shira Gabizon-Peretz, Shadan Modaresahmadi, et al.
Advanced Drug Delivery Reviews|June 12, 2020
Translational considerations in nanomedicine: The oncology perspectiveAlberto A Gabizon, Rafael T M de Rosales, Ninh M La-Beck
Therapeutics and Clinical Risk Management|March 7, 2017
Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in contextAlexander D Le, Saeed K Alzghari, Gary W Jean, et al.
Seminars in Cancer Biology|December 25, 2019
Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatmentNinh M La-Beck, Xinli Liu, Hilary Shmeeda, et al.
Pageof 4